Morgan Stanley initiated coverage on Celldex Therapeutics with a new price target

3/20/25 7:59:39 AM ET

Biotechnology: In Vitro & In Vivo Diagnostic Substances

Health Care

Morgan Stanley initiated coverage of Celldex Therapeutics with a rating of Overweight and set a new price target of $46.00

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$CLDX

Date	Price Target	Rating	Analyst
4/28/2025	$64.00	Buy	Canaccord Genuity
3/20/2025	$46.00	Overweight	Morgan Stanley
2/13/2025	$44.00	Buy	UBS
10/7/2024	$70.00	Buy	Citigroup
9/30/2024	$45.00	Neutral	Goldman
9/27/2024		Outperform → Peer Perform	Wolfe Research
6/18/2024	$58.00	Buy	Stifel
6/11/2024	$51.00	Outperform	Wolfe Research